Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel for Early Rising PSA in Prostate Cancer
NCT00714376Phase 2Terminated
- Sponsor
- CHU de Québec-Université Laval
- Start
- May 2008
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by CHU de Québec-Université Laval. Primary endpoint: Rate of partial and complete biochemical response. Started May 2008; status: terminated.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00714376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00714376.